查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916883

血流阻斷膠囊市場：全球預測（2026-2032 年），依產品類別、劑型、治療領域、包裝規格及通路分類

Duanxueliu Capsule Market by Product Class, Dosage Strength, Therapeutic Area, Packaging Size, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，血液流動阻斷膠囊市場價值為 5.4534 億美元，預計到 2026 年將成長至 5.8502 億美元，預計到 2032 年將達到 8.7654 億美元，複合年成長率為 7.01%。

主要市場統計數據
基準年 2025 5.4534億美元
預計年份：2026年 5.8502億美元
預測年份：2032年 8.7654億美元
複合年成長率 (%) 7.01%

一個涵蓋臨床定位、監管摩擦點和商業性槓桿的綜合框架，這些因素共同影響心血管和血液治療領域的產品應用。

段雪柳膠囊是心血管和血液疾病治療領域的重點治療選擇，需要生產者、支付者和臨床醫生進行策略性合作。本執行摘要了影響該產品在治療通路和分銷網路中定位的最主要結構趨勢、監管考慮和商業性優勢。

技術創新、法規環境和供應鏈轉型將如何影響膠囊治療性介入的臨床應用管道和商業策略

膠囊劑治療方法的治療和商業性格局正經歷快速變革，其驅動力包括生產製造技術的創新、監管重點的演變以及醫療服務提供者和患者期望的改變。製劑科學和精準給藥技術的進步正在降低產品差異化程度，並擴大安全性和耐受性方面的差異化潛力，這正在影響藥物上市的討論以及配藥醫生的選擇。

2025年推出和調整的關稅和貿易措施對藥品原料的持續供應、價格談判和策略採購決策產生了影響。評估供應鏈壓力和採購調整。

2025年推出調整的關稅及貿易措施再次引發人們對醫藥原料跨境供應鏈依賴性的關注。雖然關稅對成品藥的影響通常有限，但對原料藥和中間體徵收關稅可能會增加依賴國際採購的活性成分和輔料的生產商的上游成本壓力。

深入了解膠囊製劑的產品類別、劑型、治療重點、包裝和分銷管道如何推動差異化的監管和商業策略。

細分市場分析揭示了不同產品類別、劑量強度、治療領域、包裝形式和分銷管道在臨床應用、通路策略和營運重點方面存在顯著差異。鑑於非處方藥和處方箋藥產品類別之間的差異，監管文件、藥物監測和支付方互動方面的要求也存在顯著差異，因此需要製定不同的商業化藍圖。

美洲、歐洲、中東、非洲和亞太地區的區域趨勢比較，這些趨勢正在影響膠囊製劑的監管策略、採購管道和臨床應用模式。

區域趨勢對監管管道、採購實踐和臨床應用具有決定性影響，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。在美洲，市場進入討論通常聚焦於支付方的報銷框架、真實世界療效比較數據以及與心臟病學和血液病學診療路徑的整合，這些因素共同指導著藥品目錄的編制和醫院的採購決策。

競爭策略著重於證據生成、生產韌性和整合病人參與，以維持膠囊產品的差異化優勢和長期市場地位。

膠囊劑治療領域的企業競爭主要集中在透過臨床證據、生產品質和完善的患者支持項目來實現差異化。主要企業投資於有針對性的臨床研究，以證明其安全性和耐受性優勢；而營運領導企業則加強了品質系統和供應鏈監控，以最大限度地降低批間差異和監管風險。

製造商可採取的切實可行的策略重點，以確保供應韌性、產生真實世界數據、最佳化包裝和分銷管道，並整合跨部門能力以實現永續獲取。

產業領導者應優先考慮供應鏈多元化和本土化方案，以降低跨境關稅波動和物流中斷帶來的風險。對關鍵活性成分實施雙重採購策略，並合格的本地契約製造(CMO)，有助於企業在確保供應連續性的同時，遵守當地監管要求。

本研究採用混合方法研究框架，整合監管文件審查、臨床註冊分析、相關人員訪談和供應鏈圖譜分析，以產生可操作且檢驗的研究結果。

我們的研究途徑結合了對監管文件、臨床試驗註冊資訊和公開藥物監測摘要的系統性二手資料分析，以及對監管事務、採購、臨床實踐和供應鏈運營等關鍵相關人員的訪談。二級資訊來源提供了監管和臨床背景資訊，而一手研究檢驗了多個司法管轄區的運營實踐、採購行為和配銷通路趨勢。

簡明扼要地總結了將臨床潛力轉化為不同醫療保健系統中患者持續獲得醫療服務所需的營運要務和跨職能優先事項。

本執行摘要闡述了在心血管和血液疾病治療中成功應用膠囊療法所需的多方面考量。關鍵主題包括：生產和採購環節的韌性需求、上市後證據產生的重要性日益凸顯，以及包裝和分銷策略與臨床和醫療保險報銷實際情況相符的必要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：血流切割膠囊市場（依產品類別分類）

  • 非處方藥
  • 處方藥

第9章 依劑型分類的血流阻斷膠囊市場

  • 250毫克
  • 500毫克

第10章 依治療領域分類的血流切割膠囊市場

  • 循環系統
  • 血液疾病

第11章 依包裝規格分類的血流切割膠囊市場

  • 10粒膠囊
  • 20粒膠囊
  • 30粒膠囊

第12章 血流切割膠囊市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 血流切割膠囊市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血流切割膠囊市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國血流切割膠囊市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國止血膠囊市場

第17章：中國血流切割膠囊市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anhui Zhang Hengchun Pharmaceutical Co., Ltd.
  • Beijing Tong Ren Tang Co., Ltd.
  • China National Pharmaceutical Group Corporation（Sinopharm）
  • China Resources Sanjiu Medical & Pharmaceutical（Group）Co., Ltd.
  • Guizhou Hengba Pharmaceutical Co., Ltd.
  • Guizhou Xintuo Pharmaceutical Co., Ltd.
  • Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.
  • Jiangsu Kanion Pharmaceutical Co., Ltd.
  • Jilin Dongbao Pharmaceutical Co., Ltd.
  • Tasly Pharmaceutical Group Co., Ltd.
  • Yunnan Baiyao Group Co., Ltd.
  • Zhejiang Conba Pharmaceutical Co., Ltd.
Product Code: MRR-AE420CB153CE

The Duanxueliu Capsule Market was valued at USD 545.34 million in 2025 and is projected to grow to USD 585.02 million in 2026, with a CAGR of 7.01%, reaching USD 876.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 545.34 million
Estimated Year [2026] USD 585.02 million
Forecast Year [2032] USD 876.54 million
CAGR (%) 7.01%

Comprehensive framing of clinical positioning, regulatory friction points, and commercial levers that determine product adoption within cardiovascular and hematological care

Duanxueliu Capsule represents a focused therapeutic offering within cardiovascular and hematological care pathways that demands strategic attention from manufacturers, payers, and clinicians. This executive summary synthesizes the most salient structural dynamics, regulatory considerations, and commercial levers that influence how the product is positioned across treatment pathways and distribution networks.

Throughout the summary, the emphasis is on pragmatic insight rather than speculative projection. The analysis synthesizes observed regulatory approvals, prevailing clinical practice guidelines, supply chain realities, and patient access mechanisms that together shape uptake patterns. As a result, readers will gain a clear view of the operational priorities that stakeholders must address to convert clinical potential into sustained utilization.

Moreover, this introduction frames subsequent sections that examine transformative market shifts, tariff-related headwinds, product and channel segmentation, geographic differentials, competitive behaviors, recommended strategic actions, and the rigorous research approach used to compile these findings. Each section builds on empirical indicators and stakeholder intelligence to provide a coherent basis for informed decision-making.

How technological, regulatory, and supply chain transformations are reshaping clinical adoption pathways and commercial strategies for capsule-based therapeutic interventions

The therapeutic and commercial landscape for capsule-delivered therapies is undergoing rapid transformation driven by technology-enabled manufacturing, evolving regulatory priorities, and changing provider and patient expectations. Advances in formulation science and precision dosing have reduced variability and expanded the potential to differentiate products on safety and tolerability profiles, which in turn influences formulary discussions and prescriber preference.

Concurrently, digitization of medication management and telehealth adoption are altering how prescriptions are initiated, monitored, and refilled. These shifts accelerate the importance of channel optimization and patient-support solutions, and they create opportunities to capture adherence data that supports value-based contracting. In parallel, heightened scrutiny on supply chain resilience and quality oversight has pushed manufacturers to re-evaluate sourcing strategies for active ingredients and packaging inputs.

Finally, regulatory agencies have signaled greater emphasis on post-market evidence and pharmacovigilance, creating higher expectations for ongoing data generation. Taken together, these transformative shifts require integrated responses across clinical development, regulatory affairs, commercial operations, and manufacturing to sustain access and competitive differentiation.

Assessment of 2025 tariff-driven supply chain pressures and procurement adaptations that influenced continuity, pricing negotiations, and strategic sourcing decisions for pharmaceutical inputs

Tariff policies and trade measures introduced or adjusted in 2025 created renewed attention on cross-border supply chain dependencies for pharmaceutical inputs. While finished dosage forms often attract limited tariff exposure, tariffs applied to raw materials and intermediates can increase upstream cost pressure for manufacturers that rely on internationally sourced active pharmaceutical ingredients and excipients.

As a result, organizations with concentrated sourcing footprints experienced operational stress when logistics frictions and customs procedures amplified lead-time variability. Consequently, procurement teams accelerated supplier qualification and dual-sourcing initiatives to mitigate the risk of supply interruption. At the same time, regulatory-compliant domestic manufacturing capacity became a strategic priority for firms seeking to reduce exposure to trade policy volatility.

Importantly, tariff-related dynamics also influenced broader commercial conversations, including pricing negotiations with payers, contractual commitments to maintain uninterrupted supply, and decisions around inventory buffers. In response, companies prioritized transparent supplier mapping, stronger contractual protections with key vendors, and scenario planning that incorporated varying levels of cross-border tariff friction to preserve continuity of patient access.

Insights on product class, strength, therapeutic focus, packaging format, and distribution pathways that drive differentiated regulatory and commercial approaches for capsule therapies

Segmentation analysis reveals meaningful heterogeneity in clinical usage, channel strategies, and operational priorities across product class, dosage strength, therapeutic focus, packaging, and distribution pathways. When considering product class differences between over-the-counter availability and prescription-only designation, the requirements for regulatory documentation, pharmacovigilance, and payer interaction shift substantially, demanding divergent commercialization roadmaps.

Dosage strength differentiation between lower-strength and higher-strength capsule presentations affects clinical positioning and prescriber routing, with implications for labeling, dosing guidance, and interchangeability discussions. Therapeutic area distinctions between cardiovascular and hematological indications also shape evidence needs: cardiovascular applications frequently require long-term safety monitoring and outcomes-oriented data, whereas hematological indications may necessitate targeted clinical endpoints and specialist engagement.

Packaging size choices ranging from smaller blister counts to larger multi-unit packs influence adherence, cost per dispensing event, and reimbursement coding, while distribution channel strategy across hospital pharmacies, online pharmacies, and retail pharmacies determines stocking cadence, promotional tactics, and patient support workflows. Taken together, these segmentation dimensions underscore the importance of aligning regulatory, clinical, and commercial tactics to the specific product profile and route to patient.

Comparative regional dynamics across the Americas, Europe-Middle East-Africa, and Asia-Pacific that shape regulatory strategy, procurement pathways, and clinical adoption patterns for capsule therapeutics

Regional dynamics exert a decisive influence on regulatory pathways, procurement practices, and clinical adoption, with distinct patterns emerging across the Americas, Europe-Middle East-Africa, and Asia-Pacific. In the Americas, market access conversations frequently center on payer reimbursement frameworks, real-world evidence for comparative effectiveness, and integration with cardiology and hematology care pathways, which together guide formulary placement and hospital procurement decisions.

In the Europe-Middle East-Africa region, regulatory heterogeneity and centralized versus decentralized approval mechanisms require nuanced regulatory strategies and local evidence generation to satisfy national agencies and major hospital systems. Additionally, procurement consortiums and tenders in parts of this region create different commercial timelines and contractual structures that manufacturers must anticipate.

Asia-Pacific exhibits a diverse set of regulatory maturities and manufacturing capabilities, and many markets emphasize local clinical validation and price controls as conditions of market entry. Moreover, regional supply chain hubs and manufacturing ecosystems in Asia-Pacific have implications for sourcing, cost structures, and lead times for global product programs. Across all regions, tailoring engagement strategies to local payer expectations, provider behaviors, and regulatory requirements is essential for consistent access and sustained uptake.

Competitive strategies emphasizing evidence generation, manufacturing resilience, and integrated patient engagement that sustain differentiation and long-term positioning for capsule products

Competitive behavior among companies active in capsule therapeutics centers on differentiating through clinical evidence, manufacturing quality, and integrated patient support programs. Leading firms invest in targeted clinical studies that demonstrate safety and tolerability advantages, while operational leaders strengthen quality systems and supply chain oversight to minimize batch variability and regulatory risk.

Strategic partnerships and contract manufacturing relationships have become common levers for scaling production without incurring the full capital burden of new facilities. At the same time, commercialization teams focus on multichannel engagement models that connect hospital pharmacists, specialist prescribers, and retail and digital dispensing partners to streamline initiation and refill adherence. Furthermore, companies are increasingly attentive to lifecycle management opportunities such as optimized dosing regimens, patient-centric packaging, and incremental formulation improvements that extend the therapeutic relevance of capsule products.

Taken together, these competitive priorities emphasize an integrated approach that combines robust evidence generation, resilient manufacturing and procurement strategies, and proactive commercial engagement to maintain long-term positioning in therapeutic categories characterized by clinical complexity and payer scrutiny.

Actionable strategic priorities for manufacturers to secure supply resilience, generate real-world evidence, optimize packaging and channels, and align cross-functional capabilities for sustainable access

Industry leaders should prioritize supply chain diversification and onshoring options to reduce exposure to cross-border tariff shocks and logistics disruptions. By implementing dual-sourcing strategies for key active ingredients and qualifying regional contract manufacturers, organizations can preserve continuity of supply while maintaining compliance with local regulatory requirements.

In parallel, companies must accelerate post-market evidence collection and leverage real-world data streams to substantiate comparative effectiveness and long-term safety. This evidence supports constructive payer dialogues and can enable innovative contracting approaches tied to outcomes. Additionally, optimizing packaging sizes and refill paradigms to align with clinical dosing patterns and patient adherence behaviors will improve persistence and reduce medication wastage.

Commercially, expanding digital dispensing partnerships and strengthening hospital pharmacy engagement will create more predictable channels for initiation and refill management. Finally, cross-functional alignment between regulatory, medical affairs, and commercial teams is essential to translate clinical differentiation into streamlined market access pathways and durable uptake among prescribers and patients.

Mixed-methods research framework integrating regulatory document review, clinical registry analysis, stakeholder interviews, and supply chain mapping to produce actionable and verifiable insights

The research approach combined systematic secondary analysis of regulatory filings, clinical trial registries, and publicly available pharmacovigilance summaries with primary stakeholder interviews across regulatory affairs, procurement, clinical practice, and supply chain operations. Secondary sources provided the regulatory and clinical context, while primary engagements validated operational realities, procurement behaviors, and channel dynamics in multiple jurisdictions.

Analytical rigor was maintained through triangulation of documentary evidence, stakeholder insights, and supply chain mapping to identify areas of risk and opportunity. Where appropriate, scenario-based sensitivity checks were used to test the resilience of strategic recommendations against plausible changes in trade policy, manufacturing disruptions, or shifts in provider preference. All qualitative inputs were coded thematically and synthesized to preserve nuance while ensuring actionable clarity.

Finally, ethical standards and confidentiality protocols governed all primary interviews, and findings were contextualized to reflect jurisdictional regulatory differences and clinical practice variations. This mixed-methods approach ensures that conclusions are both evidence-based and operationally relevant for decision-makers across development, manufacturing, and commercial functions.

Concise synthesis of operational imperatives and cross-functional priorities required to convert clinical promise into sustained patient access across diverse healthcare systems

This executive summary underscores the multifaceted considerations required to support successful deployment of capsule therapeutics in cardiovascular and hematological care. Key themes include the imperative for manufacturing and sourcing resilience, the growing importance of post-market evidence generation, and the need to align packaging and channel strategies with clinical and reimbursement realities.

Importantly, regulatory heterogeneity across regions and heightened attention to pharmacovigilance require proactive planning and sustained investment in quality systems and evidence collection. Companies that integrate these operational priorities with focused commercial engagement and digital-enabled patient support are positioned to navigate access barriers and enhance long-term utilization.

In conclusion, translating clinical promise into sustained patient access demands coordinated action across R&D, regulatory, manufacturing, and commercial teams. The insights presented here provide a foundation for pragmatic decision-making and targeted investments that reduce execution risk and improve the likelihood of consistent therapeutic availability across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Duanxueliu Capsule Market, by Product Class

  • 8.1. Otc
  • 8.2. Prescription

9. Duanxueliu Capsule Market, by Dosage Strength

  • 9.1. 250 Mg
  • 9.2. 500 Mg

10. Duanxueliu Capsule Market, by Therapeutic Area

  • 10.1. Cardiovascular
  • 10.2. Hematological Disorders

11. Duanxueliu Capsule Market, by Packaging Size

  • 11.1. 10 Capsules
  • 11.2. 20 Capsules
  • 11.3. 30 Capsules

12. Duanxueliu Capsule Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Duanxueliu Capsule Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Duanxueliu Capsule Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Duanxueliu Capsule Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Duanxueliu Capsule Market

17. China Duanxueliu Capsule Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anhui Zhang Hengchun Pharmaceutical Co., Ltd.
  • 18.6. Beijing Tong Ren Tang Co., Ltd.
  • 18.7. China National Pharmaceutical Group Corporation (Sinopharm)
  • 18.8. China Resources Sanjiu Medical & Pharmaceutical (Group) Co., Ltd.
  • 18.9. Guizhou Hengba Pharmaceutical Co., Ltd.
  • 18.10. Guizhou Xintuo Pharmaceutical Co., Ltd.
  • 18.11. Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.
  • 18.12. Jiangsu Kanion Pharmaceutical Co., Ltd.
  • 18.13. Jilin Dongbao Pharmaceutical Co., Ltd.
  • 18.14. Tasly Pharmaceutical Group Co., Ltd.
  • 18.15. Yunnan Baiyao Group Co., Ltd.
  • 18.16. Zhejiang Conba Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DUANXUELIU CAPSULE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DUANXUELIU CAPSULE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY OTC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY OTC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY OTC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 250 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 250 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 250 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 500 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 500 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 500 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 10 CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 10 CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 10 CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 20 CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 20 CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 20 CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 30 CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 30 CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 30 CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GCC DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. GCC DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. GCC DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 103. GCC DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. G7 DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. G7 DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 120. G7 DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 121. G7 DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. NATO DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. NATO DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 126. NATO DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 127. NATO DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)